Fig. 4: Inhibition of RAS induces pancreatic tumour-selective apoptosis.
From: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
a,b, Capan-1 subcutaneous xenograft mice (from Fig. 3) were treated with a single dose of vehicle (veh) or RMC-7977 at 10 mg kg−1, 25 mg kg−1 or 50 mg kg−1. Tissues were collected at indicated timepoints (n = 3–6 per timepoint and dose). a, Representative IHC of tumours, colon and skin from the Capan-1 xenograft model collected at 8 h after a single dose of vehicle or RMC-7977, stained for CC3. Scale bars, 100 μm. b, Quantification of CC3 staining in tumours, colon, and skin. b–f, Tumour-bearing KPF/FC mice were treated with a single dose of vehicle or RMC-7977 at 10 mg kg−1, 25 mg kg−1 or 50 mg kg−1. Tissues were collected at indicated timepoints (n = 3 per timepoint and dose). c, Representative IHC of KPF/FC tumours and colons collected at 4 h after a single dose of vehicle or RMC-7977, stained for CC3. Scale bars, 50 μm. d, Quantification of CC3 staining in tumours and colons. e, Representative IHC of KPF/FC tumours and colons collected at 24 h after a single dose of vehicle or RMC-7977, stained for cyclin A2. Scale bars, 50 μm. f, Quantification of cyclin A2 staining in tumours and colons. b,d,f, Analysis of IHC based on ten fields of view and plotted as the average per tissue section. Shades of blue represent the tested doses. Results were compared by two-tailed unpaired Student’s t-test.
